Drugs / Olive oil
Olive oil
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CLINOLIPID 20% | — | 2013-10-03 | fda.gov ↗ |
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05040620 | Jan 2020 → Mar 2022 | odontoclasia | Minia University | Unknown | No outcome recorded |
| Phase 1 | NCT03544411 | Jul → Sep 2018 | hyperglycemia, lip disorder, type 2 diabetes mellitus | Indonesia University | Completed | No outcome recorded |
| Phase 1 | NCT03399331 | Jul 2017 → Dec 2021 | chemotherapy-induced oral mucositis, leukemia | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00421161 | Jan → Mar 2007 | dermatitis | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01772433 | Jan → Sep 2013 | — | Ardabil University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04717037 | Sep 2020 → Aug 2022 | neonatal sepsis | King Abdullah International Medical Research Center | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03044639 | Apr 2010 → Oct 2016 | liver failure | Stanley Dudrick's Memorial Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05585476 | Oct 2025 → Jun 2026 overdue | female breast carcinoma, female reproductive system disorder | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Not yet recruiting | No outcome recorded |
| — | NCT06070311 | Oct 2023 → Sep 2025 | chronic rhinosinusitis, nasal cavity polyp | Assiut University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05952349 Comparator | Jul → Dec 2023 | — | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05285943 Comparator | Nov 2021 → Jan 2024 | radiodermatitis | Cairo University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01418053 Comparator | Aug 2011 → Sep 2013 | irritable bowel syndrome | University of Duisburg-Essen | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLIVE OIL | “5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.” NCT03399331 ↗10“It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.” NCT05585476 ↗ “Olive oil will be used as a replacement to phonophoresis gel in this arm” NCT01772433 ↗ |
| Known as | Olea europaea fruit oil | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107910 ↗ |
| Known as | Olea europaea oil | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107910 ↗ |
| Known as | Olivae oleum (ep) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107910 ↗ |
| Known as | Olive leaf dry extract | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107910 ↗ |
| Known as | Olive oil component of smoflipid | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107910 ↗ |
| Known as | Olive oil/ LCT | “Olive oil/ LCT (80:20, OO group))” NCT03044639 ↗ |
| Modality | Other / unclassified | “olive oil and omega 3 in a combined cream” NCT00421161 ↗ |
| Route | Topical | “used externally as inunction together with a hot or cold cataplasm as assigned” NCT01418053 ↗ |